en · de · es · pt
methods-notes.peptides6908.com › Info › Melanotan-2 Identity And Receptor Pharmacology — Hands-On Walkthrough

Melanotan-2 Identity And Receptor Pharmacology — Hands-On Walkthrough

By Editorial Desk · published 2025-07-26 · last reviewed 2025-09-01 · Info

If you have been reading about afamelanotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Melanotan-2 Structure and Receptor Pharmacology

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Related pages on this site

Notes from published material

== Function == This gene encodes an actin sequestering protein which plays a role in regulation of actin polymerization. The protein is also involved in cell proliferation, migration, and differentiation. This gene escapes X inactivation and has a homolog on chromosome Y (TMSB4Y).

=== Link to cancer === Post-translational modification of proteins is a generally used mechanism in eukaryotic cell signaling. Ubiquitylation, ubiquitin conjugation to proteins, is a crucial process for cell cycle progression and cell proliferation and development. Although ubiquitylation usually serves as a signal for protein degradation through the 26S proteasome, it could also serve for other fundamental cellular processes, in endocytosis, enzymatic activation and DNA repair. Moreover, since ubiquitylation functions to tightly regulate the cellular level of cyclins, its misregulation is expected to have severe impacts. First evidence of the importance of the ubiquitin/proteasome pathway in oncogenic processes was observed due to the high antitumor activity of proteasome inhibitors. Various studies have shown that defects or alterations in ubiquitylation processes are commonly associated with or present in human carcinoma. Malignancies could be developed through loss of function mutation directly at the tumor suppressor gene, increased activity of ubiquitylation, and/or indirect attenuation of ubiquitylation due to mutation in related proteins.

Meanwhile, Gaddafi continued to have testy relationships with most of his fellow Arab leaders. In the 2003 Arab League summit, Gaddafi was involved in a public verbal altercation with Abdullah of Saudi Arabia, then the Crown Prince. Gaddafi accused Saudi Arabia of having made an "alliance with the devil" when it invited the US to intervene in the 1991 Gulf War. Abdullah responded that Gaddafi was a "liar" and an "agent of colonizers" and threatened Gaddafi that "your grave awaits you." Two weeks after the summit, Gaddafi allegedly plotted with the Emir Hamad bin Khalifa Al Thani of Qatar to assassinate Abdullah. The plot was overseen by Libyan intelligence chief Moussa Koussa, Mohammed Ismail (a colonel in Gaddafi's military intelligence), and Abdul Rahman al-Amoudi (an American citizen and founder of American Muslim Council). The assassination conspiracy was foiled by Saudi intelligence with the help of the FBI and CIA. Amoudi was sentenced to 23 years in prison in the US and stripped of his American citizenship. Ismail was arrested by Saudi Arabia, pardoned by Abdullah in 2005, and later acquired UAE citizenship due to his close ties with its ruler Mohamed bin Zayed Al Nahyan. After the failure of the assassination plot, Gaddafi continued to discuss instigating a regime change in Saudi Arabia with multiple power brokers in the Persian Gulf, including Qatar's Foreign Minister Hamad bin Jassim bin Jaber Al Thani, Oman's foreign minister Yusuf bin Alawi bin Abdullah, and Kuwaiti extremist preacher Hakem al-Mutairi.

{\displaystyle {\frac {\mathrm {d} \left[\mathrm {M} _{1}\right]}{\mathrm {d} \left[\mathrm {M} _{2}\right]}}={\frac {\left[\mathrm {M} _{1}\right]\left(r_{1}\left[\mathrm {M} _{1}\right]+\left[\mathrm {M} _{2}\right]\right)}{\left[\mathrm {M} _{2}\right]\left(\left[\mathrm {M} _{1}\right]+r_{2}\left[\mathrm {M} _{2}\right]\right)}}}

== Overdose == At doses over 20 or 30 mg orally, frightening hallucinations, as well as tachycardia, hypertension, and hyperthermia, may occur. The fatal dose of 2C-B in humans is unknown but its safety window is thought to be narrower than certain other psychedelics like LSD and psilocybin similarly to the case of mescaline. It was reported by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) that a psychologist had accidentally taken a 100 mg dose orally without apparent harm. There are three case reports of 2C-B intoxication in the scientific literature as of 2015 and no deaths have been attributed to 2C-B alone as of 2018.

Sources: en.wikipedia.org

Background from the literature

In "The Good Wives Club", it is revealed that Jimmy is claustrophobic; when he is entering the enclosed hallway he is seen sweating profusely and when he has to go get the body bag he freaks out about having to go back through it. In "About Face", as Jimmy is being hypnotised by Abby, it seems that Jimmy has a shoe fetish, as he dreamily talks in detail about Ziva and Abby's footwear instead of recalling information about the current case. The episode also indicates that his mother's name is Eunice. In the episode "Bounce" we see that Palmer regularly helps Tony when he is in charge, despite the fact that Tony has frequently mocked Palmer by calling him an "autopsy gremlin". Palmer is also shown to have severe tinnitus. Season seven reveals that Jimmy is in love with a girl named Breena Slater (Michelle Pierce), who works as a mortician in her family's funeral parlor and appears in the episode "Mother's Day". In the season eight finale, "Pyramid", NCIS special agent E.J. Barrett congratulates Jimmy on his engagement, and in the season nine premiere "Nature of the Beast", Ziva says that they are getting married next spring. In "Newborn King", Palmer is accompanied to NCIS headquarters by Breena's father, Ed Slater. Ed alternates between grating on the nerves of the entire team and mocking Palmer's career choice. Most of the team either ignore Ed or quietly tolerate his rudeness out of respect for Palmer and his guest.

Aminoacyl-tRNA synthetase enzymes consume ATP in the attachment tRNA to amino acids, forming aminoacyl-tRNA complexes. Aminoacyl transferase binds AMP-amino acid to tRNA. The coupling reaction proceeds in two steps: aa + ATP ⟶ aa-AMP + PPi aa-AMP + tRNA ⟶ aa-tRNA + AMP The amino acid is coupled to the penultimate nucleotide at the 3′-end of the tRNA (the A in the sequence CCA) via an ester bond (roll over in illustration). Transporting chemicals out of a cell against a gradient is often associated with ATP hydrolysis. Transport is mediated by ATP binding cassette transporters. The human genome encodes 48 ABC transporters, that are used for exporting drugs, lipids, and other compounds.

=== Genesis of the Israelite people === Biblically, the Israelites referred to the descendants of Israel, a view that was reinforced by Second Temple Judaism, although gentiles could fully assimilate into the Israelite community. They referred to themselves as the sons of Israel, which could possibly refer to peoplehood rather than blood descent, especially after Israel's biological family transitioned from a clan to a nation (Exodus 1:9). The Israelite identity is alternatively interpreted as being based on religious allegiance, especially through worship of Yahweh or 'covenantal circumcision'. There's also contentious evidence of Israelite tribal status being acquired through self-declared allegiance, residency within assigned tribal territory (Ezekiel 47:21–23) or forceful absorption by a greater Israelite tribe. Jason A. Staples argues that the Israelites referred to the northern Israelite tribes, especially in the Nevi'im, although it's also inclusive of the other tribes in other contexts. The Israelites trace their ancestors to Jacob, who in turn descended from Abraham. Abraham was formerly a native of Ur Kaśdim (Genesis 11:31), whose location is unknown. Some scholars argue that it is located in lower Mesopotamia whilst others locate it further north in upper Mesopotamia, around northern Syria or southeastern Turkey. Theologians suggest that Canaan always belonged to the Israelites but was initially usurped by the descendants of Canaan, resulting in their conquest by Israel as divine punishment.

=== Ulcerative colitis === Infliximab targets TNF, thought to be more related to Th1 cytokines. Ulcerative colitis was thought to be a Th2 disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

Network